导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 57.48% | 31/4773 |
| 近一周 | -1.30% | 393/5462 |
| 近一月 | -3.62% | 1866/5421 |
| 近一季 | -17.40% | 4556/5209 |
| 近半年 | 37.47% | 38/4920 |
| 近一年 | 87.25% | 35/4366 |
| 近两年 | 344.90% | 2/2954 |
| 近三年 | 324.27% | 2/2253 |
| 成立以来 | 214.13% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
11.39% 46/4961 |
88.22% 136/5312 |
- - |
- - |
| 2025 | 108.61% 11/4813 |
-3.73% 3081/3635 |
10.76% 234/4076 |
71.23% 22/4524 |
14.25% 90/4813 |
| 2024 | 29.59% 126/3463 |
3.49% 559/2808 |
2.79% 308/3014 |
13.33% 2192/3129 |
7.49% 446/3463 |
| 2023 | 21.07% 17/2656 |
23.54% 111/2280 |
12.69% 12/2385 |
-10.37% 1991/2515 |
-2.97% 561/2655 |
| 2022 | -27.38% 1474/2207 |
-23.67% 1741/1919 |
6.92% 576/2016 |
-15.02% 1195/2113 |
4.71% 514/2208 |
| 2021 | 12.85% 372/1822 |
-6.56% 1020/1255 |
12.47% 330/1330 |
-7.63% 1067/1466 |
16.27% 53/1822 |
| 2020 | - - |
- - |
16.99% 400/1067 |
-3.68% 1096/1164 |
-1.59% 1110/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 东财通信C VS. 长安沪深300非周期A(740101) |